Symbols / AZN Stock $195.17 +0.18% AstraZeneca PLC
AZN (Stock) Chart
About
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Stock Fundamentals
Scroll to Statements| Market Cap | 302.56B | Enterprise Value | 326.17B | Income | 10.23B | Sales | 58.74B | Book/sh | 31.38 | Cash/sh | 3.69 |
| Dividend Yield | 1.62% | Payout | 47.91% | Employees | 96100 | IPO | — | P/E | 29.80 | Forward P/E | 24.56 |
| PEG | 1.60 | P/S | 5.15 | P/B | 6.22 | P/C | — | EV/EBITDA | 16.92 | EV/Sales | 5.55 |
| Quick Ratio | 0.65 | Current Ratio | 0.94 | Debt/Eq | 60.97 | LT Debt/Eq | — | EPS (ttm) | 6.55 | EPS next Y | 7.95 |
| EPS Growth | 53.90% | Revenue Growth | 4.10% | Earnings | 2026-04-29 | ROA | 8.19% | ROE | 22.84% | ROIC | — |
| Gross Margin | 81.71% | Oper. Margin | 21.59% | Profit Margin | 17.41% | Shs Outstand | 1.55B | Shs Float | 1.54B | Short Float | 0.10% |
| Short Ratio | 0.83 | Short Interest | — | 52W High | 212.71 | 52W Low | 132.32 | Beta | 0.28 | Avg Volume | 2.20M |
| Volume | 628.61K | Target Price | $211.59 | Recom | Strong_buy | Prev Close | $194.81 | Price | $195.17 | Change | 0.18% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-02-13 | up | UBS | Neutral → Buy | — |
| 2024-11-20 | up | UBS | Sell → Neutral | — |
| 2024-09-11 | up | Erste Group | Hold → Buy | — |
| 2024-08-12 | main | TD Cowen | Buy → Buy | $95 |
| 2024-05-30 | main | Argus Research | Buy → Buy | $85 |
| 2024-05-30 | init | Goldman Sachs | — → Buy | $97 |
| 2024-04-26 | main | BMO Capital | Outperform → Outperform | $82 |
| 2024-04-16 | up | Deutsche Bank | Sell → Hold | — |
| 2024-02-12 | main | BMO Capital | Outperform → Outperform | $80 |
| 2024-02-08 | down | Deutsche Bank | Buy → Hold | — |
| 2024-01-23 | init | Morgan Stanley | — → Overweight | $85 |
| 2024-01-03 | down | Jefferies | Buy → Hold | — |
| 2023-09-25 | up | Jefferies | Hold → Buy | $80 |
| 2023-09-08 | down | Erste Group | Buy → Hold | — |
| 2023-08-01 | main | BMO Capital | Outperform → Outperform | $83 |
| 2023-05-26 | main | Argus Research | Buy → Buy | $80 |
| 2023-04-13 | main | Argus Research | — → Buy | $85 |
| 2023-01-05 | init | BMO Capital | — → Outperform | $82 |
| 2022-11-14 | main | SVB Leerink | — → Outperform | $79 |
| 2022-11-11 | main | SVB Leerink | — → Outperform | $78 |
News
RSS: Latest AZN news- AstraZeneca (AZN) stock falls amid market uptick: What investors need to know - MSN hu, 23 Apr 2026 10
- AstraZeneca (NYSE: AZN) board member Rene Haas to step down - Stock Titan hu, 23 Apr 2026 10
- Assessing AstraZeneca (LSE:AZN) Valuation As Strong 1‑Year Returns Contrast With Softer Recent Momentum - Yahoo Finance hu, 23 Apr 2026 00
- Astra posts trial win for Ultomiris in IgA nephropathy (AZN) - Seeking Alpha ue, 21 Apr 2026 15
- Morgan Stanley raises AstraZeneca stock price target on pipeline progress - Investing.com ue, 07 Apr 2026 07
- AstraZeneca (AZN) Stock: COPD Drug Tozorakimab Hits Phase III Trial Goals - CoinCentral Mon, 20 Apr 2026 11
- Fund Update: New $284.9M $AZN stock position opened by Artemis Investment Management LLP - Quiver Quantitative Mon, 13 Apr 2026 15
- AstraZeneca PLC (AZN) Stock Analysis: Eyeing Modest Upside Amid Strong Buy Ratings - DirectorsTalk Interviews Mon, 20 Apr 2026 09
- AstraZeneca (AZN) Seeks Accelerated Approval for Ultomiris in Ig - GuruFocus ue, 21 Apr 2026 17
- AZN Stock Gains as COPD Drug Clears Two Late-Stage Studies - Yahoo Finance Mon, 30 Mar 2026 07
- COPD patients saw fewer flare-ups in AstraZeneca's third Phase III trial - Stock Titan Mon, 20 Apr 2026 11
- Astra posts new late-stage trial win for COPD drug (AZN:NYSE) - Seeking Alpha Mon, 20 Apr 2026 12
- AstraZeneca (AZN) Reports Positive Interim Results from I CAN Tr - GuruFocus ue, 21 Apr 2026 12
- AZN vs. MRK: Which Oncology Stock Offers Better Investment Potential? - Yahoo Finance hu, 09 Apr 2026 07
- Are Medical Stocks Lagging AstraZeneca (AZN) This Year? - Yahoo Finance Mon, 13 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
58,739.00
+8.63%
|
54,073.00
+18.03%
|
45,811.00
+3.29%
|
44,351.00
|
| Operating Revenue |
|
58,739.00
+8.63%
|
54,073.00
+18.03%
|
45,811.00
+3.29%
|
44,351.00
|
| Cost Of Revenue |
|
10,633.00
+4.17%
|
10,207.00
+23.45%
|
8,268.00
-33.27%
|
12,391.00
|
| Reconciled Cost Of Revenue |
|
10,633.00
+4.17%
|
10,207.00
+23.45%
|
8,268.00
-33.27%
|
12,391.00
|
| Gross Profit |
|
48,106.00
+9.67%
|
43,866.00
+16.84%
|
37,543.00
+17.47%
|
31,960.00
|
| Operating Expense |
|
34,779.00
+3.46%
|
33,615.00
+16.63%
|
28,821.00
+5.00%
|
27,448.00
|
| Research And Development |
|
14,232.00
+4.78%
|
13,583.00
+24.22%
|
10,935.00
+12.02%
|
9,762.00
|
| Selling General And Administration |
|
20,774.00
+2.72%
|
20,224.00
+10.99%
|
18,222.00
+1.32%
|
17,984.00
|
| Selling And Marketing Expense |
|
579.00
+4.32%
|
555.00
+2.97%
|
539.00
+0.56%
|
536.00
|
| General And Administrative Expense |
|
20,195.00
+2.67%
|
19,669.00
+11.23%
|
17,683.00
+1.35%
|
17,448.00
|
| Other Operating Expenses |
|
134.00
+10.74%
|
121.00
-26.22%
|
164.00
-18.00%
|
200.00
|
| Total Expenses |
|
45,412.00
+3.63%
|
43,822.00
+18.15%
|
37,089.00
-6.90%
|
39,839.00
|
| Operating Income |
|
13,327.00
+30.01%
|
10,251.00
+17.53%
|
8,722.00
+93.31%
|
4,512.00
|
| Total Operating Income As Reported |
|
13,743.00
+37.39%
|
10,003.00
+22.09%
|
8,193.00
+118.07%
|
3,757.00
|
| EBITDA |
|
19,506.00
+26.35%
|
15,438.00
+15.02%
|
13,422.00
+47.74%
|
9,085.00
|
| Normalized EBITDA |
|
19,139.00
+22.76%
|
15,591.00
+12.08%
|
13,911.00
+41.57%
|
9,826.00
|
| Reconciled Depreciation |
|
5,490.00
+8.39%
|
5,065.00
+2.66%
|
4,934.00
-6.09%
|
5,254.00
|
| EBIT |
|
14,016.00
+35.12%
|
10,373.00
+22.21%
|
8,488.00
+121.56%
|
3,831.00
|
| Total Unusual Items |
|
367.00
+339.87%
|
-153.00
+68.71%
|
-489.00
+34.01%
|
-741.00
|
| Total Unusual Items Excluding Goodwill |
|
367.00
+339.87%
|
-153.00
+68.71%
|
-489.00
+34.01%
|
-741.00
|
| Special Income Charges |
|
416.00
+267.74%
|
-248.00
+53.12%
|
-529.00
+29.93%
|
-755.00
|
| Other Special Charges |
|
-372.00
-3000.00%
|
-12.00
-233.33%
|
9.00
-98.43%
|
573.00
|
| Impairment Of Capital Assets |
|
—
|
—
|
—
|
0.00
|
| Restructuring And Mergern Acquisition |
|
-44.00
-116.92%
|
260.00
-50.00%
|
520.00
+185.71%
|
182.00
|
| Net Income |
|
10,225.00
+45.34%
|
7,035.00
+18.14%
|
5,955.00
+81.11%
|
3,288.00
|
| Pretax Income |
|
12,402.00
+42.70%
|
8,691.00
+25.97%
|
6,899.00
+175.85%
|
2,501.00
|
| Net Non Operating Interest Income Expense |
|
-1,254.00
+6.21%
|
-1,337.00
-3.80%
|
-1,288.00
-3.12%
|
-1,249.00
|
| Interest Expense Non Operating |
|
1,614.00
-4.04%
|
1,682.00
+5.85%
|
1,589.00
+19.47%
|
1,330.00
|
| Net Interest Income |
|
-1,254.00
+6.21%
|
-1,337.00
-3.80%
|
-1,288.00
-3.12%
|
-1,249.00
|
| Interest Expense |
|
1,614.00
-4.04%
|
1,682.00
+5.85%
|
1,589.00
+19.47%
|
1,330.00
|
| Interest Income Non Operating |
|
360.00
+4.35%
|
345.00
+14.62%
|
301.00
+271.60%
|
81.00
|
| Interest Income |
|
360.00
+4.35%
|
345.00
+14.62%
|
301.00
+271.60%
|
81.00
|
| Tax Provision |
|
2,169.00
+31.45%
|
1,650.00
+75.91%
|
938.00
+218.43%
|
-792.00
|
| Tax Rate For Calcs |
|
0.00
-5.19%
|
0.00
+39.64%
|
0.00
-28.44%
|
0.00
|
| Tax Effect Of Unusual Items |
|
66.06
+327.42%
|
-29.05
+56.31%
|
-66.49
+52.78%
|
-140.79
|
| Net Income Including Noncontrolling Interests |
|
10,233.00
+45.33%
|
7,041.00
+18.12%
|
5,961.00
+81.02%
|
3,293.00
|
| Net Income From Continuing Operation Net Minority Interest |
|
10,225.00
+45.34%
|
7,035.00
+18.14%
|
5,955.00
+81.11%
|
3,288.00
|
| Net Income From Continuing And Discontinued Operation |
|
10,225.00
+45.34%
|
7,035.00
+18.14%
|
5,955.00
+81.11%
|
3,288.00
|
| Net Income Continuous Operations |
|
10,233.00
+45.33%
|
7,041.00
+18.12%
|
5,961.00
+81.02%
|
3,293.00
|
| Minority Interests |
|
-8.00
-33.33%
|
-6.00
+0.00%
|
-6.00
-20.00%
|
-5.00
|
| Normalized Income |
|
9,924.06
+38.62%
|
7,158.95
+12.25%
|
6,377.51
+64.02%
|
3,888.21
|
| Net Income Common Stockholders |
|
10,225.00
+45.34%
|
7,035.00
+18.14%
|
5,955.00
+81.11%
|
3,288.00
|
| Otherunder Preferred Stock Dividend |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Diluted EPS |
|
6.54
+45.33%
|
4.50
+18.11%
|
3.81
+80.57%
|
2.11
|
| Basic EPS |
|
6.60
+45.37%
|
4.54
+18.23%
|
3.84
+81.13%
|
2.12
|
| Basic Average Shares |
|
1,550.00
+0.00%
|
1,550.00
+0.06%
|
1,549.00
+0.06%
|
1,548.00
|
| Diluted Average Shares |
|
1,562.00
-0.06%
|
1,563.00
+0.06%
|
1,562.00
+0.13%
|
1,560.00
|
| Diluted NI Availto Com Stockholders |
|
10,225.00
+45.34%
|
7,035.00
+18.14%
|
5,955.00
+81.11%
|
3,288.00
|
| Amortization |
|
—
|
—
|
—
|
—
|
| Depreciation Income Statement |
|
—
|
—
|
—
|
—
|
| Rent Expense Supplemental |
|
452.00
+19.89%
|
377.00
+25.25%
|
301.00
+12.31%
|
268.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
114,074.00
+9.65%
|
104,035.00
+2.88%
|
101,119.00
+4.80%
|
96,483.00
|
| Current Assets |
|
28,723.00
+11.21%
|
25,827.00
+3.09%
|
25,054.00
+10.89%
|
22,593.00
|
| Cash Cash Equivalents And Short Term Investments |
|
5,719.00
+3.51%
|
5,525.00
-5.72%
|
5,860.00
-6.13%
|
6,243.00
|
| Cash And Cash Equivalents |
|
5,711.00
+4.06%
|
5,488.00
-6.03%
|
5,840.00
-5.29%
|
6,166.00
|
| Cash Equivalents |
|
4,379.00
+2.48%
|
4,273.00
-5.36%
|
4,515.00
-5.05%
|
4,755.00
|
| Cash Financial |
|
1,332.00
+9.63%
|
1,215.00
-8.30%
|
1,325.00
-6.09%
|
1,411.00
|
| Other Short Term Investments |
|
8.00
-78.38%
|
37.00
+85.00%
|
20.00
-74.03%
|
77.00
|
| Accounts Receivable |
|
10,237.00
+23.31%
|
8,302.00
-1.25%
|
8,407.00
+16.57%
|
7,212.00
|
| Gross Accounts Receivable |
|
10,289.00
+23.44%
|
8,335.00
-1.38%
|
8,452.00
+16.24%
|
7,271.00
|
| Allowance For Doubtful Accounts Receivable |
|
-52.00
-57.58%
|
-33.00
+26.67%
|
-45.00
+23.73%
|
-59.00
|
| Other Receivables |
|
2,906.00
-0.92%
|
2,933.00
+39.53%
|
2,102.00
+6.16%
|
1,980.00
|
| Taxes Receivable |
|
1,158.00
-37.71%
|
1,859.00
+30.36%
|
1,426.00
+95.08%
|
731.00
|
| Inventory |
|
6,557.00
+24.00%
|
5,288.00
-2.51%
|
5,424.00
+15.43%
|
4,699.00
|
| Raw Materials |
|
1,857.00
+24.71%
|
1,489.00
-2.74%
|
1,531.00
+7.67%
|
1,422.00
|
| Work In Process |
|
2,777.00
+21.69%
|
2,282.00
-1.85%
|
2,325.00
+24.73%
|
1,864.00
|
| Finished Goods |
|
1,923.00
+26.76%
|
1,517.00
-3.25%
|
1,568.00
+10.97%
|
1,413.00
|
| Prepaid Assets |
|
2,034.00
+17.10%
|
1,737.00
+7.42%
|
1,617.00
+21.67%
|
1,329.00
|
| Restricted Cash |
|
22.00
-82.95%
|
129.00
+26.47%
|
102.00
-37.04%
|
162.00
|
| Assets Held For Sale Current |
|
—
|
0.00
|
0.00
-100.00%
|
150.00
|
| Hedging Assets Current |
|
90.00
+66.67%
|
54.00
-53.45%
|
116.00
+33.33%
|
87.00
|
| Other Current Assets |
|
—
|
—
|
—
|
—
|
| Total Non Current Assets |
|
85,351.00
+9.13%
|
78,208.00
+2.82%
|
76,065.00
+2.94%
|
73,890.00
|
| Net PPE |
|
14,703.00
+26.24%
|
11,647.00
+10.90%
|
10,502.00
+11.14%
|
9,449.00
|
| Gross PPE |
|
25,245.00
+23.01%
|
20,522.00
+7.44%
|
19,101.00
+11.10%
|
17,192.00
|
| Accumulated Depreciation |
|
-10,542.00
-18.78%
|
-8,875.00
-3.21%
|
-8,599.00
-11.06%
|
-7,743.00
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Land And Improvements |
|
7,240.00
+10.03%
|
6,580.00
+1.72%
|
6,469.00
+18.92%
|
5,440.00
|
| Buildings And Improvements |
|
2,048.00
+28.97%
|
1,588.00
+17.46%
|
1,352.00
+14.38%
|
1,182.00
|
| Machinery Furniture Equipment |
|
11,156.00
+17.21%
|
9,518.00
+3.47%
|
9,199.00
+16.66%
|
7,885.00
|
| Construction In Progress |
|
4,740.00
+69.95%
|
2,789.00
+36.38%
|
2,045.00
-22.92%
|
2,653.00
|
| Other Properties |
|
61.00
+29.79%
|
47.00
+30.56%
|
36.00
+12.50%
|
32.00
|
| Goodwill And Other Intangible Assets |
|
59,088.00
+1.52%
|
58,202.00
+0.11%
|
58,137.00
-1.67%
|
59,127.00
|
| Goodwill |
|
21,242.00
+1.03%
|
21,025.00
+4.87%
|
20,048.00
+1.15%
|
19,820.00
|
| Other Intangible Assets |
|
37,846.00
+1.80%
|
37,177.00
-2.39%
|
38,089.00
-3.10%
|
39,307.00
|
| Long Term Equity Investment |
|
302.00
+12.69%
|
268.00
+82.31%
|
147.00
+93.42%
|
76.00
|
| Other Investments |
|
2,223.00
+36.21%
|
1,632.00
+6.67%
|
1,530.00
|
—
|
| Non Current Deferred Taxes Assets |
|
5,819.00
+8.83%
|
5,347.00
+13.33%
|
4,718.00
+44.59%
|
3,263.00
|
| Non Current Prepaid Assets |
|
559.00
+57.02%
|
356.00
+29.93%
|
274.00
+12.76%
|
243.00
|
| Total Liabilities Net Minority Interest |
|
65,355.00
+3.47%
|
63,164.00
+1.95%
|
61,953.00
+4.25%
|
59,425.00
|
| Current Liabilities |
|
30,617.00
+9.87%
|
27,866.00
-8.76%
|
30,542.00
+16.16%
|
26,293.00
|
| Payables |
|
7,501.00
-6.91%
|
8,058.00
+5.71%
|
7,623.00
+30.51%
|
5,841.00
|
| Accounts Payable |
|
3,820.00
+4.95%
|
3,640.00
+11.42%
|
3,267.00
+28.12%
|
2,550.00
|
| Other Payable |
|
2,017.00
-22.75%
|
2,611.00
+14.52%
|
2,280.00
+18.32%
|
1,927.00
|
| Total Tax Payable |
|
1,664.00
-7.91%
|
1,807.00
-12.96%
|
2,076.00
+52.20%
|
1,364.00
|
| Current Debt And Capital Lease Obligation |
|
3,013.00
+20.76%
|
2,495.00
-51.88%
|
5,185.00
-4.91%
|
5,453.00
|
| Current Debt |
|
2,631.00
+22.03%
|
2,156.00
-56.13%
|
4,914.00
-5.95%
|
5,225.00
|
| Current Capital Lease Obligation |
|
382.00
+12.68%
|
339.00
+25.09%
|
271.00
+18.86%
|
228.00
|
| Total Non Current Liabilities Net Minority Interest |
|
34,738.00
-1.59%
|
35,298.00
+12.37%
|
31,411.00
-5.19%
|
33,132.00
|
| Long Term Debt And Capital Lease Obligation |
|
26,136.00
-5.37%
|
27,619.00
+18.93%
|
23,222.00
-1.98%
|
23,690.00
|
| Long Term Debt |
|
24,715.00
-6.76%
|
26,506.00
+18.52%
|
22,365.00
-2.61%
|
22,965.00
|
| Long Term Capital Lease Obligation |
|
1,421.00
+27.67%
|
1,113.00
+29.87%
|
857.00
+18.21%
|
725.00
|
| Long Term Provisions |
|
918.00
-0.33%
|
921.00
-18.28%
|
1,127.00
+25.78%
|
896.00
|
| Defined Pension Benefit |
|
106.00
+7.07%
|
99.00
+7.61%
|
92.00
+2.22%
|
90.00
|
| Non Current Pension And Other Postretirement Benefit Plans |
|
1,105.00
-16.92%
|
1,330.00
-12.50%
|
1,520.00
+30.14%
|
1,168.00
|
| Tradeand Other Payables Non Current |
|
2,939.00
+51.26%
|
1,943.00
-25.75%
|
2,617.00
-23.92%
|
3,440.00
|
| Non Current Deferred Revenue |
|
55.00
|
0.00
-100.00%
|
7.00
-50.00%
|
14.00
|
| Non Current Deferred Taxes Liabilities |
|
3,500.00
+5.90%
|
3,305.00
+16.21%
|
2,844.00
-3.40%
|
2,944.00
|
| Stockholders Equity |
|
48,667.00
+19.32%
|
40,786.00
+4.20%
|
39,143.00
+5.69%
|
37,037.00
|
| Common Stock Equity |
|
48,667.00
+19.32%
|
40,786.00
+4.20%
|
39,143.00
+5.69%
|
37,037.00
|
| Capital Stock |
|
388.00
+0.00%
|
388.00
+0.00%
|
388.00
+0.26%
|
387.00
|
| Common Stock |
|
388.00
+0.00%
|
388.00
+0.00%
|
388.00
+0.26%
|
387.00
|
| Share Issued |
|
1,550.91
+0.02%
|
1,550.55
+0.02%
|
1,550.16
+0.02%
|
1,549.80
|
| Ordinary Shares Number |
|
1,550.76
+0.04%
|
1,550.10
0.00%
|
1,550.16
+0.02%
|
1,549.80
|
| Treasury Shares Number |
|
0.15
-66.64%
|
0.44
|
0.00
|
0.00
|
| Additional Paid In Capital |
|
35,419.00
+0.11%
|
35,379.00
+0.11%
|
35,341.00
+0.09%
|
35,308.00
|
| Retained Earnings |
|
10,972.00
+247.22%
|
3,160.00
+110.39%
|
1,502.00
+361.67%
|
-574.00
|
| Minority Interest |
|
52.00
-38.82%
|
85.00
+269.57%
|
23.00
+9.52%
|
21.00
|
| Total Equity Gross Minority Interest |
|
48,719.00
+19.20%
|
40,871.00
+4.35%
|
39,166.00
+5.69%
|
37,058.00
|
| Total Capitalization |
|
73,382.00
+9.05%
|
67,292.00
+9.40%
|
61,508.00
+2.51%
|
60,002.00
|
| Working Capital |
|
-1,894.00
+7.11%
|
-2,039.00
+62.85%
|
-5,488.00
-48.32%
|
-3,700.00
|
| Invested Capital |
|
76,013.00
+9.45%
|
69,448.00
+4.56%
|
66,422.00
+1.83%
|
65,227.00
|
| Total Debt |
|
29,149.00
-3.20%
|
30,114.00
+6.01%
|
28,407.00
-2.53%
|
29,143.00
|
| Net Debt |
|
21,635.00
-6.64%
|
23,174.00
+8.09%
|
21,439.00
-2.66%
|
22,024.00
|
| Capital Lease Obligations |
|
1,803.00
+24.17%
|
1,452.00
+28.72%
|
1,128.00
+18.36%
|
953.00
|
| Net Tangible Assets |
|
-10,421.00
+40.16%
|
-17,416.00
+8.31%
|
-18,994.00
+14.02%
|
-22,090.00
|
| Tangible Book Value |
|
-10,421.00
+40.16%
|
-17,416.00
+8.31%
|
-18,994.00
+14.02%
|
-22,090.00
|
| Available For Sale Securities |
|
2,212.00
+35.54%
|
1,632.00
+6.67%
|
1,530.00
+44.89%
|
1,056.00
|
| Current Provisions |
|
686.00
-45.94%
|
1,269.00
+23.44%
|
1,028.00
+42.38%
|
722.00
|
| Derivative Product Liabilities |
|
0.00
-100.00%
|
115.00
+202.63%
|
38.00
-95.97%
|
943.00
|
| Financial Assets |
|
498.00
+173.63%
|
182.00
-20.18%
|
228.00
+208.11%
|
74.00
|
| Financial Assets Designatedas Fair Value Through Profitor Loss Total |
|
11.00
|
0.00
|
0.00
-100.00%
|
10.00
|
| Investmentin Financial Assets |
|
2,223.00
+36.21%
|
1,632.00
+6.67%
|
1,530.00
+43.53%
|
1,066.00
|
| Non Current Accrued Expenses |
|
85.00
+30.77%
|
65.00
+80.56%
|
36.00
-2.70%
|
37.00
|
| Preferred Shares Number |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
14,575.00
+22.88%
|
11,861.00
+14.65%
|
10,345.00
+5.48%
|
9,808.00
|
| Net Income From Continuing Operations |
|
12,402.00
+42.70%
|
8,691.00
+25.97%
|
6,899.00
+175.85%
|
2,501.00
|
| Depreciation |
|
1,283.00
+12.35%
|
1,142.00
+13.29%
|
1,008.00
-8.20%
|
1,098.00
|
| Amortization Cash Flow |
|
4,207.00
+7.24%
|
3,923.00
-0.08%
|
3,926.00
-5.53%
|
4,156.00
|
| Depreciation And Amortization |
|
5,490.00
+8.39%
|
5,065.00
+2.66%
|
4,934.00
-6.09%
|
5,254.00
|
| Other Non Cash Items |
|
1,819.00
+19.12%
|
1,527.00
+5.24%
|
1,451.00
+127.07%
|
639.00
|
| Gain Loss On Investment Securities |
|
49.00
+151.58%
|
-95.00
-137.50%
|
-40.00
-185.71%
|
-14.00
|
| Net Foreign Currency Exchange Gain Loss |
|
31.00
-26.19%
|
42.00
+23.53%
|
34.00
+112.50%
|
16.00
|
| Gain Loss On Sale Of PPE |
|
-168.00
-162.50%
|
-64.00
+74.50%
|
-251.00
-141.35%
|
-104.00
|
| Change In Working Capital |
|
-1,137.00
-27.32%
|
-893.00
-397.67%
|
300.00
-92.01%
|
3,757.00
|
| Change In Receivables |
|
-1,728.00
-6.40%
|
-1,624.00
-13.96%
|
-1,425.00
-5.63%
|
-1,349.00
|
| Change In Inventory |
|
-755.00
-476.34%
|
-131.00
+80.42%
|
-669.00
-116.98%
|
3,941.00
|
| Change In Payable |
|
1,346.00
+56.15%
|
862.00
-63.99%
|
2,394.00
+105.49%
|
1,165.00
|
| Investing Cash Flow |
|
-6,808.00
+14.69%
|
-7,980.00
-96.36%
|
-4,064.00
-37.30%
|
-2,960.00
|
| Net PPE Purchase And Sale |
|
-2,797.00
-49.65%
|
-1,869.00
-52.07%
|
-1,229.00
-51.92%
|
-809.00
|
| Purchase Of PPE |
|
-2,810.00
-46.05%
|
-1,924.00
-41.37%
|
-1,361.00
-24.75%
|
-1,091.00
|
| Sale Of PPE |
|
13.00
-76.36%
|
55.00
-58.33%
|
132.00
-53.19%
|
282.00
|
| Capital Expenditure |
|
-5,905.00
-28.76%
|
-4,586.00
-21.39%
|
-3,778.00
-46.95%
|
-2,571.00
|
| Net Investment Purchase And Sale |
|
-98.00
-916.67%
|
12.00
+271.43%
|
-7.00
+94.02%
|
-117.00
|
| Purchase Of Investment |
|
-229.00
-138.54%
|
-96.00
+29.41%
|
-136.00
+14.47%
|
-159.00
|
| Sale Of Investment |
|
131.00
+21.30%
|
108.00
-16.28%
|
129.00
+207.14%
|
42.00
|
| Net Business Purchase And Sale |
|
-1,240.00
+68.42%
|
-3,927.00
-233.08%
|
-1,179.00
-11.12%
|
-1,061.00
|
| Purchase Of Business |
|
-1,240.00
+68.53%
|
-3,940.00
-234.18%
|
-1,179.00
-11.12%
|
-1,061.00
|
| Gain Loss On Sale Of Business |
|
—
|
—
|
0.00
|
0.00
|
| Net Intangibles Purchase And Sale |
|
-2,959.00
-16.54%
|
-2,539.00
-19.43%
|
-2,126.00
-105.81%
|
-1,033.00
|
| Purchase Of Intangibles |
|
-3,095.00
-16.27%
|
-2,662.00
-10.14%
|
-2,417.00
-63.31%
|
-1,480.00
|
| Net Other Investing Changes |
|
—
|
—
|
190.00
|
—
|
| Financing Cash Flow |
|
-7,544.00
-88.79%
|
-3,996.00
+39.15%
|
-6,567.00
+3.75%
|
-6,823.00
|
| Net Issuance Payments Of Debt |
|
-1,650.00
-191.21%
|
1,809.00
+287.46%
|
-965.00
+19.38%
|
-1,197.00
|
| Issuance Of Debt |
|
15.00
-99.77%
|
6,492.00
+70.13%
|
3,816.00
|
0.00
|
| Repayment Of Debt |
|
-2,029.00
+56.38%
|
-4,652.00
+5.87%
|
-4,942.00
-288.83%
|
-1,271.00
|
| Long Term Debt Issuance |
|
15.00
-99.77%
|
6,492.00
+70.13%
|
3,816.00
|
0.00
|
| Long Term Debt Payments |
|
-2,029.00
+56.38%
|
-4,652.00
+5.87%
|
-4,942.00
-288.83%
|
-1,271.00
|
| Net Long Term Debt Issuance |
|
-2,014.00
-209.46%
|
1,840.00
+263.41%
|
-1,126.00
+11.41%
|
-1,271.00
|
| Net Short Term Debt Issuance |
|
364.00
+1274.19%
|
-31.00
-119.25%
|
161.00
+117.57%
|
74.00
|
| Net Common Stock Issuance |
|
-481.00
-1018.60%
|
-43.00
-230.30%
|
33.00
+13.79%
|
29.00
|
| Common Stock Dividend Paid |
|
-4,971.00
-7.39%
|
-4,629.00
-3.30%
|
-4,481.00
-2.68%
|
-4,364.00
|
| Cash Dividends Paid |
|
-4,971.00
-7.39%
|
-4,629.00
-3.30%
|
-4,481.00
-2.68%
|
-4,364.00
|
| Net Other Financing Charges |
|
-70.00
+91.43%
|
-817.00
+7.79%
|
-886.00
+15.38%
|
-1,047.00
|
| Changes In Cash |
|
223.00
+293.91%
|
-115.00
+59.79%
|
-286.00
-1244.00%
|
25.00
|
| Effect Of Exchange Rate Changes |
|
46.00
+149.46%
|
-93.00
-55.00%
|
-60.00
+25.00%
|
-80.00
|
| Beginning Cash Position |
|
5,429.00
-3.69%
|
5,637.00
-5.78%
|
5,983.00
-0.91%
|
6,038.00
|
| End Cash Position |
|
5,698.00
+4.95%
|
5,429.00
-3.69%
|
5,637.00
-5.78%
|
5,983.00
|
| Free Cash Flow |
|
8,670.00
+19.18%
|
7,275.00
+10.78%
|
6,567.00
-9.26%
|
7,237.00
|
| Common Stock Issuance |
|
-481.00
-1018.60%
|
-43.00
-230.30%
|
33.00
+13.79%
|
29.00
|
| Interest Paid CFO |
|
-1,316.00
-0.23%
|
-1,313.00
-21.46%
|
-1,081.00
-27.33%
|
-849.00
|
| Interest Received CFI |
|
286.00
-16.62%
|
343.00
+19.51%
|
287.00
+378.33%
|
60.00
|
| Issuance Of Capital Stock |
|
-481.00
-1018.60%
|
-43.00
-230.30%
|
33.00
+13.79%
|
29.00
|
| Sale Of Business |
|
0.00
-100.00%
|
13.00
|
0.00
|
0.00
|
| Sale Of Intangibles |
|
136.00
+10.57%
|
123.00
-57.73%
|
291.00
-34.90%
|
447.00
|
| Taxes Refund Paid |
|
-2,845.00
-3.45%
|
-2,750.00
-16.23%
|
-2,366.00
-45.78%
|
-1,623.00
|
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|